乳腺癌新辅助内分泌治疗最新研究进展  

The Recent Development of Research for Breast Cancer Neoadjuvant Endocrine Therapy

作　　者：程敏怡 王坤[1,2] 

机构地区：[1]南方医科大学,广州510515 [2]广东省人民医院肿瘤中心广东省医学科学院,广州510080

出　　处：《循证医学》2016年第2期119-124,共6页The Journal of Evidence-Based Medicine

摘　　要：新辅助内分泌治疗在激素受体阳性乳腺癌中应用,可使肿瘤降期、提高手术切除率。围绕乳腺癌新辅助内分泌治疗适宜人群,最佳疗程,与新辅助化疗、新辅助内分泌治疗药物间的疗效的对比,新辅助内分泌治疗疗效评价及预测,生物标志物等方面展开阐述,探讨目前乳腺癌新辅助内分泌治疗研究中的问题及发展趋势。Neoadjuvant endocrine therapy,a considerable treatment for hormone receptor-positive patients,can achieve the purpose of downsizing primary tumors and a high operability. This article consists of several parts：Selective patients,treatment duration,neoadjuvant chemotherapy vs. endocrine therapy,assessment of efficacy and possible predictive biomarkers etc. Results from present clinical trials will contribute to future investigation to establish the optimized treatments in individual patients.

关 键 词：乳腺癌 新辅助治疗 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]